MAP3K7 and metabolic dysfunction-associated steatohepatitis: According to a mechanistic study, CYLD directly interacts with TAK1 and deubiquitinates it, thereby inhibiting the overactivation of the JNK-p38 signaling pathway, which is crucial for the inflammation and metabolism of hyper-nourished NASH (39).